Just one small IPO priced this week, raising $6 million. Two SPACS also listed. Four IPOs and two SPACs submitted initial filings. This week’s sole listing belonged to OS Therapies (OSTX), which priced its downsized IPO at the $4...read more
OS Therapies, a Phase 2 biotech developing an off-the-shelf immunotherapy for osteosarcoma, raised $6 million by offering 1.6 million shares at the $4 proposed price. At pricing, the company commands a market cap of $81 million. OS Therapies is developing...read more
OS Therapies, a Phase 2 biotech developing an off-the-shelf immunotherapy for osteosarcoma, withdrew its filing for an initial public offering on Thursday, before refiling with new terms and underwriters within hours. The Rockville, MD-based company now plans...read more
Eight issuers began trading this past week, six of which are eligible for inclusion in our IPO stats. All eight are based outside of the US, and most of the deals downsized at pricing. Two blank check IPOs also debuted. Three small IPOs and one SPAC submitted...read more
US IPO Weekly Recap: August kicks off with one small pricing
Just one small IPO priced this week, raising $6 million. Two SPACS also listed. Four IPOs and two SPACs submitted initial filings. This week’s sole listing belonged to OS Therapies (OSTX), which priced its downsized IPO at the $4...read more
Osteosarcoma biotech OS Therapies prices downsized IPO at $4
OS Therapies, a Phase 2 biotech developing an off-the-shelf immunotherapy for osteosarcoma, raised $6 million by offering 1.6 million shares at the $4 proposed price. At pricing, the company commands a market cap of $81 million. OS Therapies is developing...read more
Osteosarcoma biotech OS Therapies withdraws and then refiles for an $8 million IPO
OS Therapies, a Phase 2 biotech developing an off-the-shelf immunotherapy for osteosarcoma, withdrew its filing for an initial public offering on Thursday, before refiling with new terms and underwriters within hours. The Rockville, MD-based company now plans...read more
US IPO Weekly Recap: 1Q IPO market wraps up with eight foreign issuers
Eight issuers began trading this past week, six of which are eligible for inclusion in our IPO stats. All eight are based outside of the US, and most of the deals downsized at pricing. Two blank check IPOs also debuted. Three small IPOs and one SPAC submitted...read more